3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
2
Recruiting
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Conditions
Osteosarcoma
1
Cognitive Dysfunction
1
Chemotherapy-Related Cognitive Impairment
1
Interventions
Cisplatin
509
Cyclophosphamide
360
Carboplatin
352
Radiotherapy
350
Capecitabine
329
Paclitaxel
325
Oxaliplatin
324
Gemcitabine
319
Docetaxel
311
Fluorouracil
284
Drug Therapy
244
apatinib
242
Bevacizumab
230
camrelizumab
214
Etoposide
200
Irinotecan
177
Doxorubicin
175
Leucovorin
162
Dexamethasone
160
sintilimab
142
pembrolizumab
140
anlotinib
136
Pemetrexed
136
Cytarabine
136
toripalimab
129
Neoadjuvant Therapy
122
S 1 (combination)
120
Vincristine
119
Rituximab
117
Radiosurgery
117
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Interventional
×
Ashwagandha
×
Clear all
NCT04092647
2023-06-15
Ashwagandha for Cognitive Dysfunction
Sutter Health
Phase 2
Unknown
80 enrolled
NCT00689195
2011-06-23
OSCAT
Tata Memorial Hospital
Phase 1/2
Unknown
24 enrolled